Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 8Recruiting 4Terminated 3Active not recruiting 3Not yet recruiting 2Unknown 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Gynecologic 2

Conditions

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1Endometrial Neoplasms 1Carcinoma, Endometrioid 1

Interventions

pembrolizumab 223Cyclophosphamide 192Radiotherapy 183Nivolumab 181Carboplatin 153Cisplatin 114Paclitaxel 112Dexamethasone 110Radiosurgery 103Magnetic Resonance Spectroscopy 97Surveys and Questionnaires 90Ipilimumab 81Doxorubicin 79Lenalidomide 76Rituximab 75durvalumab 74atezolizumab 72Radiation 72fludarabine 68Standard of Care 68Gemcitabine 68venetoclax 67Specimen Handling 65Etoposide 64Capecitabine 64Bevacizumab 62Oxaliplatin 59Docetaxel 58Biopsy 58Radiotherapy, Intensity-Modulated 56

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × Hysterectomy × Clear all
NCT02598219 2026-03-18

SENTIRAD

Centre Oscar Lambret

Phase 3 Active not recruiting
262 enrolled

Carcinoma, Endometrioid

NCT04604613 2026-03-09

Prediction of Recurrence Among Low Risk Endometrial Cancer Patients

M.D. Anderson Cancer Center

Active not recruiting
518 enrolled
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

NCT06800677 2025-01-30

BioMEC

University of Manchester

Active not recruiting
200 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡